Subscribe
istock-487063216professor25
Professor25 / iStockphoto.com
24 July 2018Americas

Allergan-tribe ruling raises questions over immunity at PTAB: lawyers

The US Court of Appeals for the Federal Circuit’s ruling that tribal sovereign immunity doesn’t apply in inter partes review (IPR) proceedings has sparked questions over state protections at the Patent Trial and Appeal Board (PTAB).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit refuses tribal immunity rehearing
23 October 2018   In a blow to Allergan and the Saint Regis Mohawk Tribe, the US Court of Appeals for the Federal Circuit yesterday refused to reconsider an earlier decision that rejected use of tribal sovereign immunity in inter partes reviews.
Americas
Mohawk tribe and Allergan seek en banc hearing in Restasis case
21 August 2018   Allergan and the Saint Regis Mohawk Tribe asked the full US Court of Appeals for the Federal Circuit on Friday to review an earlier decision that rejected use of tribal sovereign immunity in the inter partes review.
Americas
Tribal immunity not applicable in IPR, says Fed Circuit
20 July 2018   Allergan and the Saint Regis Mohawk Tribe suffered a blow today as the US Court of Appeals for the Federal Circuit affirmed a decision rejecting use of tribal sovereign immunity in the inter partes review.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle
Barnes & Thornburg reveals five new IP leaders